Elanix Biotechnologies AG raises EUR 1.5 million in two financing rounds

Towards the end of August Elanix completed two capital increases totalling EUR 1.5 Million through placing assigned number of shares to 3 qualified investors. The secured funds will enable the company to enlarge its team, scale up sales activities and expand its cell-tech OTC (Over the Counter) ointments. The expansion focus is initially aimed on Europe.

Prior to the financing round Elanix introduced Tomas Svoboda as the new sole Chief Executive Officer (CEO). Svoboda was the CEO of the private Swiss based Elanix entities since their inception in 2013. Svoboda counts more than 30 years of experience in the life science industry, working in medical devices, in-vitro diagnostics, drug delivery, contract engineering and e-health in six different countries. Following over 16 years working in international life science corporations (Serono, Haemonetics, Boston Scientific), Svoboda moved into the entrepreneurial environment in 2000. He has since then co-founded and/or managed five medical device start-ups but also participated in executive-in-residence assignments for several medical corporations.

"Elanix is entering an exciting new stage of corporate development and growth following the reverse merger onto the Frankfurt Stock Exchange from last December. Our key focus will be in helping to grow the company by executing its business plan around 3 product categories. We plan to establishing cooperation and partnership agreements with third parties around the world to meet our ambitious sales, distribution and development objectives with our cell technology platform in order to treat or save ever more patients", stated Svoboda.

Additional staff and larger offices
Elanix has further reported that the hiring process was completed successfully. Four additional life science professionals for its Swiss Headquarters in Nyon have been hired. They will move into their new offices before end of September will be pursuing the execution of agreed business plan and commercial activities through three distinct business units - OTC (Over the Counter), TEP (Tissue Engineering Products) and CaaS (cells as a service).

About Elanix Biotechnologies
Elanix Biotechnologies (Frankfurt: ELN) develops and commercializes tissue regeneration products for acute wound care, dermatological and gynaecological applications, and provides services in cell technologies. The company was founded in 2013 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working cell banks with vast quantities of cells of different cell types. The Company is headquartered in Nyon, Switzerland with offices in Potsdam and listed on the Frankfurt stock exchange under the symbol ELN.

(RAN)